Consequently, IRC117539-induced AR depletion achieves selective and potent loss-of-viability in AR-positive prostate cancer cell lines, suggesting that pharmacologic manipulation of sumoylation may be a viable treatment strategy in solid tumors as well. This evidence concerns the gene AR and prostate cancer.